Today we bring back popular guest Dr. David Russler-Germain, a Hematology/Oncology Fellow at the Washington University School of Medicine in St. Louis, to discuss his thoughts on PhD programs (in response to a listener question) as well as his take on Idecabtagene vicleucel for multiple myeloma.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.67 Thoughts on PhD Programs and Idecabtagene Vicleucel with Dr. David Russler-Germain

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.67 Thoughts on PhD Programs and Idecabtagene Vicleucel with Dr. David Russler-Germain

Download our free app to listen on your phone